<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665635</url>
  </required_header>
  <id_info>
    <org_study_id>105/17- Ov01</org_study_id>
    <nct_id>NCT04665635</nct_id>
  </id_info>
  <brief_title>Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery</brief_title>
  <official_title>Comparison of Rectosigmoid Resection and Seromuscular Tumor Shaving Methods in Ovarian Cancer Surgery (BROSEOC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cukurova University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian cancer is the most common cause of death in gynecological cancer. Approximately 75%&#xD;
      of epithelial ovarian cancers are detected at an advanced stage. Metastasis and spread are&#xD;
      mostly through transperitoneal planting and neighborhood by shedding from the ovarian&#xD;
      surface. Metastasis mostly occurs in the peritoneum, omentum, and intestines. The&#xD;
      rectosigmoid colon is the main part of the intestine affected by metastasis due to its&#xD;
      neighborhood.&#xD;
&#xD;
      Treatment in ovarian cancer consists of a combination of cytoreduction surgery and&#xD;
      platinum-based chemotherapy. Surgery is the basis of the treatment, and the main goal is to&#xD;
      achieve no residual visible tumor (complete cytoreduction: R0). The residual tumor is one of&#xD;
      the main factors affecting survival and reflects the possibilities of the surgical center and&#xD;
      the team. Multiple surgical procedures (total hysterectomy, bilateral salpingo-oophorectomy,&#xD;
      total omentectomy, peritonectomy, retroperitoneal lymphadenectomies such as pelvic and&#xD;
      paraaortic, bowel resections, splenectomy, distal pancreatectomy, various resections related&#xD;
      to the bladder, liver, stomach, and diaphragm) may be required to achieve complete or optimal&#xD;
      cytoreduction.&#xD;
&#xD;
      In the involvement of the rectosigmoid colon, primarily the serosa, then the muscular layer&#xD;
      and finally the mucosa are infiltrated due to the nature of the spread, and therefore most of&#xD;
      the involvement is observed in the seromuscular layer. In seromuscular infiltration,&#xD;
      resection of the rectosigmoid colon or shaving of tumoral implants without resection can be&#xD;
      performed. There are advantages and disadvantages of each method in terms of morbidity.&#xD;
      Although there are retrospective studies evaluating recurrence and survival between both&#xD;
      methods, as far as investigators know, no randomized prospective studies have been conducted&#xD;
      comparing these two methods. The investigators designed this study to compare these two&#xD;
      methods successfully applied in our clinic in a prospective randomized study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local pelvic recurrence</measure>
    <time_frame>0-60 months.</time_frame>
    <description>Only the pelvic recurrences determined after the last chemotherapy cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>0-60 months.</time_frame>
    <description>The time from the last chemotherapy cycle to determination of any recurrence in any location.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival</measure>
    <time_frame>0-100 months</time_frame>
    <description>Time from diagnosis to the death date due to ovarian cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery related morbidities</measure>
    <time_frame>90 days.</time_frame>
    <description>Any surgery related morbidity during 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of life</measure>
    <time_frame>0-24 months.</time_frame>
    <description>HRQoL will be assessed with the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (EORTC QLQ-C30 version 3.0).The QLQ-C30 is a 30-item questionnaire that includes five multiitem functional scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), five single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, and diarrhoea), a question on financial impact; and a two-item global quality of life scale.The questionnaire generally has a four-point response scale (1 = &quot;not at all&quot;, 4 = &quot;very much&quot;).The questionnaire is planned to be performed within 1-2 weeks prior to the surgery (baseline), after 3-4 weeks of surgery before starting of adjuvant chemotherapy, at the end of adjuvant chemotherapy, and every three months in follow-up, until two years of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>0-100 months.</time_frame>
    <description>Time from diagnosis to the death date due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Rectosigmoid Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Rectosigmoid resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectosigmoid seromuscular tumor shaving</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectosigmoid resection</intervention_name>
    <description>Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.</description>
    <arm_group_label>Rectosigmoid resection</arm_group_label>
    <arm_group_label>Rectosigmoid seromuscular tumor shaving</arm_group_label>
    <other_name>Rectosigmoid seromuscular tumor shaving</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Epithelial ovarian cancer&#xD;
&#xD;
          -  Negative colonoscopy ( no mucosal involvement)&#xD;
&#xD;
          -  Intraoperative confirmed serosal or seromuscular rectosigmoid infiltration&#xD;
&#xD;
          -  ECOG &lt;3&#xD;
&#xD;
          -  ASA &lt;3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nonepithelial ovarian cancers&#xD;
&#xD;
          -  Rectosigmoid mucosal infiltration&#xD;
&#xD;
          -  Total or subtotal colectomy necessitating large bowel infiltrations&#xD;
&#xD;
          -  ECOG &gt;2&#xD;
&#xD;
          -  ASA &gt;2&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ghanim Khatib, MD</last_name>
    <phone>+903223386060</phone>
    <email>ghanim.khatib@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ghanim Khatib, MD</last_name>
      <phone>03223386060</phone>
      <email>ghanim.khatib@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ghanim Khatib, MD</last_name>
      <phone>+903223386060</phone>
      <phone_ext>Khatib</phone_ext>
      <email>ghanim.khatib@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ghanim Khatib, MD,Ass.Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganim Khatib, MD, MSc</last_name>
      <phone>+9005326745044</phone>
      <email>ghanim.khatib@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Erkilinç S, Karataşli V, Demir B, Çakir İ, Can B, Karadeniz T, Gökçü M, Sanci M. Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes. Int J Gynecol Cancer. 2018 Nov;28(9):1699-1705. doi: 10.1097/IGC.0000000000001368.</citation>
    <PMID>30371561</PMID>
  </reference>
  <results_reference>
    <citation>Gallotta V, Fanfani F, Vizzielli G, Panico G, Rossitto C, Gagliardi ML, Margariti PA, Salerno MG, Zannoni GF, Pacelli F, Scambia G, Fagotti A. Douglas peritonectomy compared to recto-sigmoid resection in optimally cytoreduced advanced ovarian cancer patients: analysis of morbidity and oncological outcome. Eur J Surg Oncol. 2011 Dec;37(12):1085-92. doi: 10.1016/j.ejso.2011.09.003. Epub 2011 Sep 25.</citation>
    <PMID>21945640</PMID>
  </results_reference>
  <results_reference>
    <citation>Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006 Oct;203(4):521-6. Epub 2006 Aug 23.</citation>
    <PMID>17000396</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cukurova University</investigator_affiliation>
    <investigator_full_name>Ghanim Khatib</investigator_full_name>
    <investigator_title>Associate professor, MD</investigator_title>
  </responsible_party>
  <keyword>epithelial ovarian cancer</keyword>
  <keyword>Rectosigmoid resection</keyword>
  <keyword>Seromuscular tumor shaving</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

